3 Global Penny Stocks With Market Caps Under US$2B

Recent developments in global markets have been marked by a mix of optimism around AI advancements and concerns over inflation, which have influenced various sectors differently. Amid these conditions, investors are increasingly exploring diverse opportunities, including penny stocks—an investment area that remains relevant despite its somewhat outdated name. These stocks often represent smaller or less-established companies that can offer unique growth potential when backed by strong financials.

Here we highlight a subset of our preferred stocks from the screener.

National Bank of Umm Al-Qaiwain (PSC) (ADX:NBQ)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: National Bank of Umm Al-Qaiwain (PSC) provides retail and corporate banking services in the United Arab Emirates and has a market capitalization of AED5.80 billion.

Operations: The bank's revenue is primarily derived from Treasury and Investments, which contribute AED489.90 million, and Retail and Corporate Banking, generating AED309.43 million.

Market Cap: AED5.8B

National Bank of Umm Al-Qaiwain (PSC) demonstrates a stable financial foundation with its appropriate loans-to-deposits ratio of 51% and high-quality earnings. Despite recent challenges, such as a slight decline in net income for the second quarter compared to last year, the bank maintains a healthy profit margin and low-risk funding structure, primarily relying on customer deposits. While its return on equity is relatively low at 8.4%, the bank's assets-to-equity ratio is conservative at 3.7x, indicating prudent financial management. However, recent earnings growth has slowed to 0.7%, below both its historical average and industry benchmarks.

• Click here and access our complete financial health analysis report to understand the dynamics of National Bank of Umm Al-Qaiwain (PSC).
• Evaluate National Bank of Umm Al-Qaiwain (PSC)'s historical performance by accessing our past performance report.

China Dongxiang (Group) (SEHK:3818)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: China Dongxiang (Group) Co., Ltd. operates in the design, development, and sale of sport-related apparel, footwear, and accessories both in China and internationally, with a market cap of approximately HK$1.67 billion.

Operations: The company's revenue is primarily derived from its China sporting goods segment, which generated CN¥1.72 billion.

Market Cap: HK$1.67B

China Dongxiang (Group) Co., Ltd. faces challenges as it remains unprofitable with a negative return on equity of -1.81%. Despite this, the company has more cash than total debt and its short-term assets of CN¥5.5 billion far exceed both short and long-term liabilities, suggesting strong liquidity management. The experienced board and management team, each averaging 6.4 years in tenure, provide stability amidst financial hurdles. Shareholders have not faced significant dilution recently, while stable weekly volatility indicates consistent market performance despite ongoing losses which have increased by 0.2% annually over the past five years.

• Unlock comprehensive insights into our analysis of China Dongxiang (Group) stock in this financial health report.
• Learn about China Dongxiang (Group)'s historical performance here.

Fangzhou (SEHK:6086)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Fangzhou Inc. offers online chronic disease management services in China and has a market cap of approximately HK$1.18 billion.

Operations: The company's revenue is primarily generated from Online Retail Pharmacy Services (CN¥2.10 billion), Wholesale (CN¥868.24 million), Comprehensive Medical Services (CN¥810.12 million), and Customized Content and Marketing Solutions (CN¥74.16 million).

Market Cap: HK$1.18B

Fangzhou Inc. has recently achieved profitability, with a net income of CN¥8.91 million for the half-year ended June 30, 2026, despite a decline from CN¥12.48 million the previous year. The company shows strong liquidity with short-term assets exceeding liabilities and more cash than total debt, which is well covered by operating cash flow. However, its return on equity remains low at 2.8%. While management is experienced with an average tenure of 2.1 years, the board's relative inexperience could pose challenges as Fangzhou navigates growth opportunities in China's online chronic disease management sector.

• Take a closer look at Fangzhou's potential here in our financial health report.
• Evaluate Fangzhou's prospects by accessing our earnings growth report.

Next Steps

• Investigate our full lineup of 3,638 Global Penny Stocks right here.
• Looking For Alternative Opportunities? Rare earth metals are the new gold rush. Find out which 34 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com